company background image
A005

Green Cross Holdings KOSE:A005250 Stock Report

Last Price

₩16.30k

Market Cap

₩732.4b

7D

2.8%

1Y

-46.6%

Updated

01 Oct, 2022

Data

Company Financials
A005250 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance2/6
Financial Health4/6
Dividends2/6

A005250 Stock Overview

Green Cross Holdings Corporation operates as a biotechnology company.

Green Cross Holdings Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Green Cross Holdings
Historical stock prices
Current Share Price₩16,300.00
52 Week High₩32,800.00
52 Week Low₩14,950.00
Beta1.21
1 Month Change-11.65%
3 Month Change-13.53%
1 Year Change-46.65%
3 Year Change-17.47%
5 Year Change-57.33%
Change since IPO889.02%

Recent News & Updates

Shareholder Returns

A005250KR BiotechsKR Market
7D2.8%-0.7%-6.1%
1Y-46.6%-48.4%-29.0%

Return vs Industry: A005250 exceeded the KR Biotechs industry which returned -48.4% over the past year.

Return vs Market: A005250 underperformed the KR Market which returned -29% over the past year.

Price Volatility

Is A005250's price volatile compared to industry and market?
A005250 volatility
A005250 Average Weekly Movement4.4%
Biotechs Industry Average Movement7.4%
Market Average Movement5.9%
10% most volatile stocks in KR Market10.6%
10% least volatile stocks in KR Market3.6%

Stable Share Price: A005250 is less volatile than 75% of KR stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: A005250's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1967154Il-Sup Huhhttps://www.greencross.com

Green Cross Holdings Corporation operates as a biotechnology company. The company provides plasma derivatives, prescription drugs, over the counter drugs, and hunter syndrome drugs; and vaccines for hemorrhagic fever, varicella, hepatitis-B, and flu. It also researches and develops oncology, immunology, and cell therapy products; and offers recombinant protein treatment for hemophilia.

Green Cross Holdings Fundamentals Summary

How do Green Cross Holdings's earnings and revenue compare to its market cap?
A005250 fundamental statistics
Market Cap₩732.43b
Earnings (TTM)₩31.91b
Revenue (TTM)₩2.06t

22.9x

P/E Ratio

0.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
A005250 income statement (TTM)
Revenue₩2.06t
Cost of Revenue₩1.35t
Gross Profit₩710.75b
Other Expenses₩678.83b
Earnings₩31.91b

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)710.26
Gross Margin34.55%
Net Profit Margin1.55%
Debt/Equity Ratio56.8%

How did A005250 perform over the long term?

See historical performance and comparison

Dividends

2.5%

Current Dividend Yield

57%

Payout Ratio
We’ve recently updated our valuation analysis.

Valuation

Is A005250 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A005250?

Other financial metrics that can be useful for relative valuation.

A005250 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.2x
Enterprise Value/EBITDA12.9x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does A005250's PE Ratio compare to its peers?

A005250 PE Ratio vs Peers
The above table shows the PE ratio for A005250 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average25.1x
A086900 Medy-Tox
21.2x14.4%₩649.7b
A290650 L&C Bio
43.4xn/a₩543.3b
A214450 PharmaResearch
13.3x18.0%₩564.6b
22.3x25.2%₩1.2t
A005250 Green Cross Holdings
22.9xn/a₩732.4b

Price-To-Earnings vs Peers: A005250 is good value based on its Price-To-Earnings Ratio (22.9x) compared to the peer average (25.1x).


Price to Earnings Ratio vs Industry

How does A005250's PE Ratio compare vs other companies in the KR Biotechs Industry?

Price-To-Earnings vs Industry: A005250 is expensive based on its Price-To-Earnings Ratio (22.9x) compared to the KR Biotechs industry average (20.1x)


Price to Earnings Ratio vs Fair Ratio

What is A005250's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A005250 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio22.9x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate A005250's Price-To-Earnings Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of A005250 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A005250 (₩16300) is trading above our estimate of fair value (₩9046.98)

Significantly Below Fair Value: A005250 is trading above our estimate of fair value.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Green Cross Holdings forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


20.9%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Green Cross Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

Past Performance

How has Green Cross Holdings performed over the past 5 years?

Past Performance Score

2/6

Past Performance Score 2/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


0.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: A005250 has a large one-off gain of ₩48.3B impacting its June 30 2022 financial results.

Growing Profit Margin: A005250's current net profit margins (1.6%) are lower than last year (1.6%).


Past Earnings Growth Analysis

Earnings Trend: A005250's earnings have grown by 0.2% per year over the past 5 years.

Accelerating Growth: A005250's earnings growth over the past year (10.7%) exceeds its 5-year average (0.2% per year).

Earnings vs Industry: A005250 earnings growth over the past year (10.7%) underperformed the Biotechs industry 33.4%.


Return on Equity

High ROE: A005250's Return on Equity (5.6%) is considered low.


Discover strong past performing companies

Financial Health

How is Green Cross Holdings's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: A005250's short term assets (₩1,363.4B) exceed its short term liabilities (₩1,003.4B).

Long Term Liabilities: A005250's short term assets (₩1,363.4B) exceed its long term liabilities (₩614.7B).


Debt to Equity History and Analysis

Debt Level: A005250's net debt to equity ratio (39.2%) is considered satisfactory.

Reducing Debt: A005250's debt to equity ratio has increased from 43.8% to 56.8% over the past 5 years.

Debt Coverage: A005250's debt is not well covered by operating cash flow (11.2%).

Interest Coverage: A005250's interest payments on its debt are well covered by EBIT (4.6x coverage).


Balance Sheet


Discover healthy companies

Dividend

What is Green Cross Holdings's current dividend yield, its reliability and sustainability?

Dividend Score

2/6

Dividend Score 2/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


2.45%

Current Dividend Yield

Dividend Yield vs Market

Green Cross Holdings Dividend Yield vs Market
How does Green Cross Holdings dividend yield compare to the market?
SegmentDividend Yield
Company (Green Cross Holdings)2.5%
Market Bottom 25% (KR)1.1%
Market Top 25% (KR)3.6%
Industry Average (Biotechs)0.7%
Analyst forecast in 3 Years (Green Cross Holdings)n/a

Notable Dividend: A005250's dividend (2.45%) is higher than the bottom 25% of dividend payers in the KR market (1.14%).

High Dividend: A005250's dividend (2.45%) is low compared to the top 25% of dividend payers in the KR market (3.57%).


Stability and Growth of Payments

Stable Dividend: A005250 has been paying a dividend for less than 10 years and during this time payments have been volatile.

Growing Dividend: A005250's dividend payments have increased, but the company has only paid a dividend for 3 years.


Earnings Payout to Shareholders

Earnings Coverage: With its reasonable payout ratio (56.9%), A005250's dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: A005250 is paying a dividend but the company has no free cash flows.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Il-Sup Huh (68 yo)

no data

Tenure

Mr. Il-Sup Huh, Ph.D. has been the Chairperson of GC Pharma (formerly, Green Cross Corporation) since 2009 and serves as its Chief Executive Officer. Mr. Huh serves as Chairperson and Chief Executive Offic...


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of A005250?
Owner TypeNumber of SharesOwnership Percentage
Private Companies4,102,1909.1%
Institutions8,464,09918.8%
General Public15,668,90634.9%
Individual Insiders16,698,99537.2%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 25 shareholders own 65.12% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
28.98%
Il-Sup Huh
13,022,411₩212.3b3.54%no data
9.13%
MOGAM Biotechnology Research Institute
4,102,190₩66.9b0%no data
7.2%
National Pension Service
3,235,818₩52.7b0%0.03%
5.1%
Yong-Tae Park
2,290,190₩37.3b0%no data
4.58%
Mirae Nanum Foundation, Endowment Arm
2,059,600₩33.6b0%no data
3.04%
Yong-jun Hur
1,367,454₩22.3b0%no data
2.2%
Mogam Science Scholarship Foundation., Endowment Arm
986,480₩16.1b0%no data
2%
The Vanguard Group, Inc.
896,826₩14.6b1.18%no data
0.69%
BlackRock, Inc.
310,788₩5.1b0.25%no data
0.66%
Norges Bank Investment Management
297,347₩4.8b0%no data
0.65%
Dimensional Fund Advisors LP
294,145₩4.8b0.71%no data
0.21%
Charles Schwab Investment Management, Inc.
93,203₩1.5b2.9%no data
0.19%
BNY Mellon Asset Management
86,819₩1.4b2.96%no data
0.14%
State Street Global Advisors, Inc.
61,852₩1.0b1.18%no data
0.083%
Mirae Asset Global Investments Co., Ltd
37,074₩604.3m0%no data
0.059%
Thrivent Investment Management, Inc.
26,657₩434.5m0%no data
0.057%
Teachers Insurance and Annuity Association-College Retirement Equities Fund
25,795₩420.5m0%no data
0.045%
Geode Capital Management, LLC
20,216₩329.5m-0.17%no data
0.036%
Northern Trust Global Investments
16,013₩261.0m0%no data
0.021%
Goldman Sachs Asset Management, L.P.
9,482₩154.6m-10.93%no data
0.019%
Je-Tae Moon
8,350₩136.1m0%no data
0.013%
Do-Gyu Jeon
5,888₩96.0m0%no data
0.0067%
Eaton Vance Management
3,020₩49.2m0%no data
0.0064%
American Century Investment Management Inc
2,875₩46.9m-0.52%no data
0.0051%
Pyung-Ju Jang
2,302₩37.5m0%no data

Company Information

Green Cross Holdings Corporation's employee growth, exchange listings and data sources


Key Information

  • Name: Green Cross Holdings Corporation
  • Ticker: A005250
  • Exchange: KOSE
  • Founded: 1967
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: ₩732.427b
  • Shares outstanding: 44.93m
  • Website: https://www.greencross.com

Number of Employees


Location

  • Green Cross Holdings Corporation
  • 107, Ihyeon-ro 30beon-gil
  • Giheung-gu
  • Yongin-Si
  • Gyeonggi-do
  • South Korea


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
A005250KOSE (Korea Stock Exchange)YesCommon StockKRKRWJan 1992
A005257KOSE (Korea Stock Exchange)2nd Preferred SharesKRKRWJan 1998

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/10/01 00:00
End of Day Share Price2022/09/30 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.